News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Epigenomics AG Announces 2018 Second Quarter and Six Month Financial Results

PDF Berlin (Germany) and San Diego, CA (U.S.A.), August 8, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced its financial results for the second quarter and the first six months 2018 ending June 30. “While we continue to pursue our objective of Medicare coverage for Epi proColon® in the U.S., we […]

Read more

Liquid Biopsy Test for Liver Cancer Detection to obtain CE Mark

PDF -Epigenomics plans to CE Mark mSEPT9 blood test for liver cancer by year-end 2018, enabling commercialization in Europe -Prospective U.S. trial for FDA submission to be initiated in 2019 -Investigating optimal path for CFDA approval in China Berlin (Germany) and San Diego, CA (U.S.A.), July 2, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) […]

Read more

Centers for Medicare & Medicaid Services publish preliminary rate for Epigenomics’ colorectal cancer screening test Epi proColon®

PDF Medicare Administrative Contractors determine rate of $192 per test Berlin (Germany) and Germantown, MD (U.S.A.), June 11, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that the Centers for Medicare & Medicaid Services (CMS) published a preliminary rate of $192 per Epi proColon test. Epi proColon is the first and only FDA-approved […]

Read more

Epigenomics AG announces 2018 First Quarter Financial Results

PDF Berlin (Germany) and Germantown, MD (U.S.A.), May 9, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY), or the “Company”, today announced its financial results for the first quarter 2018 ended March 31. Q1/2018 Financial results -Total revenue slightly increased to EUR 309 thousand (Q1 2017: EUR 281 thousand) due to higher product sales (+38%). […]

Read more

Epigenomics AG: Blood test shows promise in the detection of liver cancer

PDF -Results from two clinical studies demonstrate high sensitivity and specificity of mSEPT9 blood test -mSEPT9 test exhibited higher diagnostic accuracy than currently established diagnostic marker -Further independent, prospective clinical study with 440 patients initiated Berlin (Germany) and Germantown, MD (U.S.A.), April 19, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced promising results […]

Read more

Epigenomics AG Reports Results for Financial Year 2017

PDF Berlin (Germany) and Germantown, MD (U.S.A.), March 23, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), or the “Company”, today announced its financial results (according to IFRS) for the year ended December 31, 2017. KEY HIGHLIGHTS Financial Total revenue of EUR 1.9 million EBITDA (before share-based payment expenses) loss of EUR 9.4 […]

Read more
...